Search research articles
Contact Us
Filters
Showing results (1-10 of 38) with videos related to
Page
of 4
Sort By:
Plos One
|
May 17, 2023
NAV-001, a high-efficacy antibody-drug conjugate targeting mesothelin with improved delivery of a potent payload by counteracting MUC16/CA125 inhibitory effects
Nicholas C Nicolaides, J Bradford Kline, Luigi Grasso
Antibody Therapeutics
|
June 30, 2025
Bypassing the immunosuppressive effects of CA125/MUC16 via re-engineered rituximab (NAV-006) to improve its antitumor activity <i>in vivo</i>
Luigi Grasso, Bradford J Kline, Nicholas C Nicolaides
Expert Opinion on Drug Discovery
|
July 26, 2012
Advances in targeted therapeutic agents
Nicholas C Nicolaides, Philip M Sass, Luigi Grasso
Oncology Letters
|
November 25, 2021
Block-Removed Immunoglobulin Technology to enhance rituximab effector function by counteracting CA125-mediated immunosuppression
Luigi Grasso, James Bradford Kline, Nicholas C Nicolaides
BMC Cancer
|
June 19, 2026
NAV-005, a high-affinity MUC16/CA125 antagonist for the treatment of humoral immunosuppressed cancers
Nicholas C Nicolaides, James Bradford Kline, Luigi Grasso
European Journal of Immunology
|
March 20, 2025
ICAM-1 Is Overexpressed by Cancers and Negatively Impacts Antibody-Based Therapies Including Antibody-Drug Conjugates
J Bradford Kline, Luigi Grasso, Nicholas C Nicolaides
Frontiers in Oncology
|
July 2, 2014
Co-development of diagnostic vectors to support targeted therapies and theranostics: essential tools in personalized cancer therapy
Nicholas C Nicolaides, Daniel J O'Shannessy, Earl Albone, et al.
Molecular and Cellular Biology
|
July 16, 2004
Gene expression analysis of tumor spheroids reveals a role for suppressed DNA mismatch repair in multicellular resistance to alkylating agents
Giulio Francia, Shan Man, Beverly Teicher, et al.
European Journal of Immunology
|
May 5, 2023
NAV-003, a bispecific antibody targeting a unique mesothelin epitope and CD3ε with improved cytotoxicity against humoral immunosuppressed tumors
Luigi Grasso, Qun Jiang, Raffit Hassan, et al.
Reproductive Toxicology (Elmsford, N.Y.)
|
June 22, 2018
Farletuzumab, a monoclonal antibody directed against folate receptor alpha, shows no evidence of teratogenicity in cynomolgus monkeys
Tomoyuki Moriyama, Dai Kakiuchi, Luigi Grasso, et al.
Page
of 4
Search research articles
Search
Showing results (1-10 of 38) with videos related to
Sort By:
Page
of 4
Plos One
|
May 17, 2023
NAV-001, a high-efficacy antibody-drug conjugate targeting mesothelin with improved delivery of a potent payload by counteracting MUC16/CA125 inhibitory effects
Nicholas C Nicolaides, J Bradford Kline, Luigi Grasso
Antibody Therapeutics
|
June 30, 2025
Bypassing the immunosuppressive effects of CA125/MUC16 via re-engineered rituximab (NAV-006) to improve its antitumor activity <i>in vivo</i>
Luigi Grasso, Bradford J Kline, Nicholas C Nicolaides
Expert Opinion on Drug Discovery
|
July 26, 2012
Advances in targeted therapeutic agents
Nicholas C Nicolaides, Philip M Sass, Luigi Grasso
Oncology Letters
|
November 25, 2021
Block-Removed Immunoglobulin Technology to enhance rituximab effector function by counteracting CA125-mediated immunosuppression
Luigi Grasso, James Bradford Kline, Nicholas C Nicolaides
BMC Cancer
|
June 19, 2026
NAV-005, a high-affinity MUC16/CA125 antagonist for the treatment of humoral immunosuppressed cancers
Nicholas C Nicolaides, James Bradford Kline, Luigi Grasso
European Journal of Immunology
|
March 20, 2025
ICAM-1 Is Overexpressed by Cancers and Negatively Impacts Antibody-Based Therapies Including Antibody-Drug Conjugates
J Bradford Kline, Luigi Grasso, Nicholas C Nicolaides
Frontiers in Oncology
|
July 2, 2014
Co-development of diagnostic vectors to support targeted therapies and theranostics: essential tools in personalized cancer therapy
Nicholas C Nicolaides, Daniel J O'Shannessy, Earl Albone, et al.
Molecular and Cellular Biology
|
July 16, 2004
Gene expression analysis of tumor spheroids reveals a role for suppressed DNA mismatch repair in multicellular resistance to alkylating agents
Giulio Francia, Shan Man, Beverly Teicher, et al.
European Journal of Immunology
|
May 5, 2023
NAV-003, a bispecific antibody targeting a unique mesothelin epitope and CD3ε with improved cytotoxicity against humoral immunosuppressed tumors
Luigi Grasso, Qun Jiang, Raffit Hassan, et al.
Reproductive Toxicology (Elmsford, N.Y.)
|
June 22, 2018
Farletuzumab, a monoclonal antibody directed against folate receptor alpha, shows no evidence of teratogenicity in cynomolgus monkeys
Tomoyuki Moriyama, Dai Kakiuchi, Luigi Grasso, et al.
Page
of 4